175 related articles for article (PubMed ID: 19184608)
1. Comment on Shuhaibar et al.: Favourable effect of immunomodulator therapy on bone mineral density in multiple sclerosis.
Kampman MT; Steffensen LH
Ir J Med Sci; 2009 Jun; 178(2):235-6; author reply 237-8. PubMed ID: 19184608
[No Abstract] [Full Text] [Related]
2. Favorable effect of immunomodulator therapy on bone mineral density in multiple sclerosis.
Shuhaibar M; McKenna MJ; Au-Yeong M; Redmond JM
Ir J Med Sci; 2009 Mar; 178(1):43-5. PubMed ID: 19002746
[TBL] [Abstract][Full Text] [Related]
3. Newer long-term treatments for multiple sclerosis.
Pryse-Phillips W
Clin Neurol Neurosurg; 2002 Jul; 104(3):265-71. PubMed ID: 12127666
[No Abstract] [Full Text] [Related]
4. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.
Frohman EM; Racke M; van Den Noort S
Arch Neurol; 2000 Jul; 57(7):930-2. PubMed ID: 10891973
[No Abstract] [Full Text] [Related]
5. [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept].
Kornhuber ME; Zierz S
Nervenarzt; 2003 Jun; 74(6):537-8; discussion 539. PubMed ID: 12799792
[No Abstract] [Full Text] [Related]
6. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].
Federal service on surveillance in healthcare and social development (Roszdravnadzor)
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163
[No Abstract] [Full Text] [Related]
7. [Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis].
Tilbery CP; Moreira MA; Mendes MF; Lana-Peixoto MA
Arq Neuropsiquiatr; 2000 Sep; 58(3A):769-76. PubMed ID: 10973126
[TBL] [Abstract][Full Text] [Related]
8. Disease modifying treatment in multiple sclerosis.
Fuller GN; Bone I
J Neurol Neurosurg Psychiatry; 2001 Dec; 71 Suppl 2(Suppl 2):ii20-1. PubMed ID: 11701780
[No Abstract] [Full Text] [Related]
9. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035
[TBL] [Abstract][Full Text] [Related]
10. Editorial: the pitfalls of combination therapy.
Vermersch P
Int MS J; 2006 Nov; 13(3):75-6. PubMed ID: 17101074
[No Abstract] [Full Text] [Related]
11. Consensus statement of the Canadian MS CLinics Network on: the use of disease modifying agents in multiple sclerosis.
Oger J; Freedman M
Can J Neurol Sci; 1999 Nov; 26(4):274-5. PubMed ID: 10610197
[No Abstract] [Full Text] [Related]
12. Interferon beta and glatiramer acetate therapy.
McGraw CA; Lublin FD
Neurotherapeutics; 2013 Jan; 10(1):2-18. PubMed ID: 23264098
[TBL] [Abstract][Full Text] [Related]
13. Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort.
Pereira VC; Malfetano FR; Meira ID; Souza LF; Liem AM; Maiolino A; Alves-Leon SV
Arq Neuropsiquiatr; 2012 Oct; 70(10):774-9. PubMed ID: 23060103
[TBL] [Abstract][Full Text] [Related]
14. [Pathogenesis and treatment of multiple sclerosis (state of the art in 2000)].
Zavalishin IA; Zhuchenko TD; Peresedova AV
Vestn Ross Akad Med Nauk; 2001; (7):18-22. PubMed ID: 11523422
[TBL] [Abstract][Full Text] [Related]
15. Factors leading patients to discontinue multiple sclerosis therapies.
Daugherty KK; Butler JS; Mattingly M; Ryan M
J Am Pharm Assoc (2003); 2005; 45(3):371-5. PubMed ID: 15991759
[TBL] [Abstract][Full Text] [Related]
16. Multiple sclerosis treatment 2001.
Rolak LA
Neurol Clin; 2001 Feb; 19(1):107-18. PubMed ID: 11471759
[TBL] [Abstract][Full Text] [Related]
17. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.
Tremlett HL; Oger J
Neurology; 2003 Aug; 61(4):551-4. PubMed ID: 12939437
[TBL] [Abstract][Full Text] [Related]
18. Newer versus older treatments for relapsing-remitting multiple sclerosis.
Weinstock-Guttman B; Cohen JA
Drug Saf; 1996 Feb; 14(2):121-30. PubMed ID: 8852526
[TBL] [Abstract][Full Text] [Related]
19. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
20. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]